<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986232</url>
  </required_header>
  <id_info>
    <org_study_id>V221-011</org_study_id>
    <secondary_id>2009_667</secondary_id>
    <nct_id>NCT00986232</nct_id>
  </id_info>
  <brief_title>ProQuad Dose Selection Study (V221-011)(COMPLETED)</brief_title>
  <official_title>A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II
      and PUVV (Process Upgrade Varicella Vaccine) vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">September 2000</completion_date>
  <primary_completion_date type="Actual">April 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Antibody response to Varicella at 6 weeks postvaccination in participants with baseline titer &lt;1.25 gpELISA units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 207.5 mIU/mL</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Antibody response to measles at 6 weeks postvaccination in participants initially seronegative (a titer &lt;207.5 mIU/mL) to measles at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 2.0 Ab Units/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to Mumps at 6 weeks postvaccination in participants initially seronegative (a titer &lt; 2.0 Ab units/mL) to Mumps at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody response to Rubella at 6 weeks postvaccination in participants initially seronegative (a titer &lt;10 IU/mL) to Rubella at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences (CAEs)</measure>
    <time_frame>6 weeks Postvaccination Visit 1 or Visit 2</time_frame>
    <description>Participants with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response to Varicella at 6 Weeks Postvaccination in Participants With Baseline Titer &lt; 1.25 gpELISA Units - Geometric Mean Titer (GMT)</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer (GMT) of Varicella antibody. (Titers measured using Varicella zoster virus (VZV) gpELISA.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response to Measles at 6 Weeks Postvaccination in Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer (GMT) of Measles antibody. (Titers measured using Measles ELISA.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response to Mumps at 6 Weeks Postvaccination in Participants Initially Seronegative to Mumps at Baseline - Geometric Mean Titer (GMT)</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer (GMT) of Mumps antibody. (Titer measured using Mumps ELISA.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response to Rubella at 6 Weeks Postvaccination in Participants Initially Seronegative to Rubella at Baseline - Geometric Mean Titer (GMT)</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer (GMT) of Rubella antibody. (Titers measured using Rubella ELISA.)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1551</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad (low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad (middle dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad (high dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M-M-R II + PUVV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live</intervention_name>
    <description>a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>ProQuad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: M-M-R II</intervention_name>
    <description>A single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: PUVV</intervention_name>
    <description>A single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  Negative clinical history of measles, mumps, rubella, varicella, and zoster

        Exclusion Criteria:

          -  Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or
             in combination

          -  Any immune impairment or deficiency

          -  Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to
             vaccination

          -  Vaccination with an inactive vaccine with in the past 14 days

          -  Vaccination with a live vaccine within the past 30 days

          -  Immune globulin or any blood product administered in the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, Meissner HC, Guerrero J, Klopfer SO, Xu J, Schödel F, Kuter BJ; Dose Selection Study Group for Proquad. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005 Aug;24(8):670-5. Erratum in: Pediatr Infect Dis J. 2005 Nov;24(11):983.</citation>
    <PMID>16094218</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <results_first_submitted>January 25, 2010</results_first_submitted>
  <results_first_submitted_qc>January 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2010</results_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>18 clinical sites in the United States
Date first participant visit: 08-Apr-1999
Date last participant visit: 03-Apr-2000</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ProQuad™ (Low Dose)</title>
          <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="P2">
          <title>ProQuad™ (Middle Dose)</title>
          <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="P3">
          <title>ProQuad™ (High Dose)</title>
          <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="P4">
          <title>M-M-R™ II + PUVV (Process Upgrade Varicella Vaccine)</title>
          <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="393">Excludes 1 patient who was randomized to receive ProQuad (Middle Dose), but was not vaccinated.</participants>
                <participants group_id="P3" count="381"/>
                <participants group_id="P4" count="390">Excludes 1 patient who was randomized to receive M-M-R™ II + PUVV, but was not vaccinated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="393"/>
                <participants group_id="P3" count="381"/>
                <participants group_id="P4" count="390"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="365"/>
                <participants group_id="P3" count="360"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="336"/>
                <participants group_id="P2" count="343"/>
                <participants group_id="P3" count="346"/>
                <participants group_id="P4" count="370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed one or more bleeds</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incomplete safety follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ProQuad™ (Low Dose)</title>
          <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="B2">
          <title>ProQuad™ (Middle Dose)</title>
          <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="B3">
          <title>ProQuad™ (High Dose)</title>
          <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="B4">
          <title>M-M-R™ II + PUVV (Process Upgrade Varicella Vaccine)</title>
          <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="387"/>
            <count group_id="B2" value="393"/>
            <count group_id="B3" value="381"/>
            <count group_id="B4" value="390"/>
            <count group_id="B5" value="1551"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" spread="1.5"/>
                    <measurement group_id="B2" value="12.9" spread="1.5"/>
                    <measurement group_id="B3" value="12.9" spread="1.5"/>
                    <measurement group_id="B4" value="13.0" spread="1.7"/>
                    <measurement group_id="B5" value="12.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="161"/>
                    <measurement group_id="B5" value="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="229"/>
                    <measurement group_id="B5" value="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="251"/>
                    <measurement group_id="B4" value="262"/>
                    <measurement group_id="B5" value="1021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units</title>
        <description>Antibody response to Varicella at 6 weeks postvaccination in participants with baseline titer &lt;1.25 gpELISA units</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to varicella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units</title>
          <description>Antibody response to Varicella at 6 weeks postvaccination in participants with baseline titer &lt;1.25 gpELISA units</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to varicella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="303"/>
                <count group_id="O5" value="307"/>
                <count group_id="O6" value="309"/>
                <count group_id="O7" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="299"/>
                    <measurement group_id="O3" value="253"/>
                    <measurement group_id="O4" value="303"/>
                    <measurement group_id="O5" value="272"/>
                    <measurement group_id="O6" value="306"/>
                    <measurement group_id="O7" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 207.5 mIU/mL</title>
        <description>Antibody response to measles at 6 weeks postvaccination in participants initially seronegative (a titer &lt;207.5 mIU/mL) to measles at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 207.5 mIU/mL</title>
          <description>Antibody response to measles at 6 weeks postvaccination in participants initially seronegative (a titer &lt;207.5 mIU/mL) to measles at baseline</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="342"/>
                <count group_id="O4" value="328"/>
                <count group_id="O5" value="323"/>
                <count group_id="O6" value="326"/>
                <count group_id="O7" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O2" value="311"/>
                    <measurement group_id="O3" value="338"/>
                    <measurement group_id="O4" value="327"/>
                    <measurement group_id="O5" value="321"/>
                    <measurement group_id="O6" value="326"/>
                    <measurement group_id="O7" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 2.0 Ab Units/mL</title>
        <description>Antibody response to Mumps at 6 weeks postvaccination in participants initially seronegative (a titer &lt; 2.0 Ab units/mL) to Mumps at baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 2.0 Ab Units/mL</title>
          <description>Antibody response to Mumps at 6 weeks postvaccination in participants initially seronegative (a titer &lt; 2.0 Ab units/mL) to Mumps at baseline</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="331"/>
                <count group_id="O5" value="331"/>
                <count group_id="O6" value="335"/>
                <count group_id="O7" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="322"/>
                    <measurement group_id="O3" value="344"/>
                    <measurement group_id="O4" value="330"/>
                    <measurement group_id="O5" value="325"/>
                    <measurement group_id="O6" value="335"/>
                    <measurement group_id="O7" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL</title>
        <description>Antibody response to Rubella at 6 weeks postvaccination in participants initially seronegative (a titer &lt;10 IU/mL) to Rubella at baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL</title>
          <description>Antibody response to Rubella at 6 weeks postvaccination in participants initially seronegative (a titer &lt;10 IU/mL) to Rubella at baseline</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="333"/>
                <count group_id="O5" value="333"/>
                <count group_id="O6" value="335"/>
                <count group_id="O7" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="319"/>
                    <measurement group_id="O3" value="343"/>
                    <measurement group_id="O4" value="332"/>
                    <measurement group_id="O5" value="326"/>
                    <measurement group_id="O6" value="335"/>
                    <measurement group_id="O7" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences (CAEs)</title>
        <description>Participants with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose).</description>
        <time_frame>6 weeks Postvaccination Visit 1 or Visit 2</time_frame>
        <population>All participants with follow-up for safety were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences (CAEs)</title>
          <description>Participants with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose).</description>
          <population>All participants with follow-up for safety were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="353"/>
                <count group_id="O3" value="387"/>
                <count group_id="O4" value="361"/>
                <count group_id="O5" value="377"/>
                <count group_id="O6" value="358"/>
                <count group_id="O7" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious Vaccine-Related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious Vaccine-Related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="353"/>
                    <measurement group_id="O3" value="386"/>
                    <measurement group_id="O4" value="361"/>
                    <measurement group_id="O5" value="377"/>
                    <measurement group_id="O6" value="358"/>
                    <measurement group_id="O7" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response to Varicella at 6 Weeks Postvaccination in Participants With Baseline Titer &lt; 1.25 gpELISA Units - Geometric Mean Titer (GMT)</title>
        <description>Postvaccination observed Geometric Mean Titer (GMT) of Varicella antibody. (Titers measured using Varicella zoster virus (VZV) gpELISA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Varicella at 6 Weeks Postvaccination in Participants With Baseline Titer &lt; 1.25 gpELISA Units - Geometric Mean Titer (GMT)</title>
          <description>Postvaccination observed Geometric Mean Titer (GMT) of Varicella antibody. (Titers measured using Varicella zoster virus (VZV) gpELISA.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="303"/>
                <count group_id="O5" value="307"/>
                <count group_id="O6" value="309"/>
                <count group_id="O7" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="5.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="167.7" lower_limit="145.6" upper_limit="193.2"/>
                    <measurement group_id="O3" value="10.5" lower_limit="9.4" upper_limit="11.7"/>
                    <measurement group_id="O4" value="381.0" lower_limit="335.8" upper_limit="432.4"/>
                    <measurement group_id="O5" value="11.9" lower_limit="10.8" upper_limit="13.1"/>
                    <measurement group_id="O6" value="469.4" lower_limit="405.5" upper_limit="543.4"/>
                    <measurement group_id="O7" value="16.5" lower_limit="15.1" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response to Measles at 6 Weeks Postvaccination in Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)</title>
        <description>Postvaccination observed Geometric Mean Titer (GMT) of Measles antibody. (Titers measured using Measles ELISA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Measles at 6 Weeks Postvaccination in Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)</title>
          <description>Postvaccination observed Geometric Mean Titer (GMT) of Measles antibody. (Titers measured using Measles ELISA.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="342"/>
                <count group_id="O4" value="328"/>
                <count group_id="O5" value="323"/>
                <count group_id="O6" value="326"/>
                <count group_id="O7" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.8" lower_limit="229.9" upper_limit="275.8"/>
                    <measurement group_id="O2" value="549.7" lower_limit="484.8" upper_limit="623.4"/>
                    <measurement group_id="O3" value="309.5" lower_limit="280.8" upper_limit="341.3"/>
                    <measurement group_id="O4" value="783.0" lower_limit="681.8" upper_limit="899.1"/>
                    <measurement group_id="O5" value="315.4" lower_limit="286.4" upper_limit="347.3"/>
                    <measurement group_id="O6" value="747.9" lower_limit="656.9" upper_limit="851.7"/>
                    <measurement group_id="O7" value="253.5" lower_limit="230.5" upper_limit="278.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response to Mumps at 6 Weeks Postvaccination in Participants Initially Seronegative to Mumps at Baseline - Geometric Mean Titer (GMT)</title>
        <description>Postvaccination observed Geometric Mean Titer (GMT) of Mumps antibody. (Titer measured using Mumps ELISA.)</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Mumps at 6 Weeks Postvaccination in Participants Initially Seronegative to Mumps at Baseline - Geometric Mean Titer (GMT)</title>
          <description>Postvaccination observed Geometric Mean Titer (GMT) of Mumps antibody. (Titer measured using Mumps ELISA.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="322"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="331"/>
                <count group_id="O5" value="331"/>
                <count group_id="O6" value="335"/>
                <count group_id="O7" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.0" lower_limit="90.0" upper_limit="115.7"/>
                    <measurement group_id="O2" value="277.7" lower_limit="252.0" upper_limit="305.9"/>
                    <measurement group_id="O3" value="106.3" lower_limit="94.4" upper_limit="119.8"/>
                    <measurement group_id="O4" value="244.1" lower_limit="220.3" upper_limit="270.3"/>
                    <measurement group_id="O5" value="114.7" lower_limit="101.3" upper_limit="130.0"/>
                    <measurement group_id="O6" value="286.0" lower_limit="259.2" upper_limit="315.7"/>
                    <measurement group_id="O7" value="97.4" lower_limit="87.5" upper_limit="108.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response to Rubella at 6 Weeks Postvaccination in Participants Initially Seronegative to Rubella at Baseline - Geometric Mean Titer (GMT)</title>
        <description>Postvaccination observed Geometric Mean Titer (GMT) of Rubella antibody. (Titers measured using Rubella ELISA.)</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ (Low Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ (Low Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ (Middle Dose) After 1 Injection</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O4">
            <title>ProQuad™ (Middle Dose) After 2 Injections</title>
            <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O5">
            <title>ProQuad™ (High Dose) After 1 Injection</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O6">
            <title>ProQuad™ (High Dose) After 2 Injections</title>
            <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
          </group>
          <group group_id="O7">
            <title>M-M-R™ II + PUVV After 1 Injection</title>
            <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Rubella at 6 Weeks Postvaccination in Participants Initially Seronegative to Rubella at Baseline - Geometric Mean Titer (GMT)</title>
          <description>Postvaccination observed Geometric Mean Titer (GMT) of Rubella antibody. (Titers measured using Rubella ELISA.)</description>
          <population>The per-protocol analysis set included participants who had pre- and post-randomization blood samples within predefined day ranges and followed protocol procedures.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="319"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="333"/>
                <count group_id="O5" value="333"/>
                <count group_id="O6" value="335"/>
                <count group_id="O7" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.4" lower_limit="119.6" upper_limit="144.5"/>
                    <measurement group_id="O2" value="263.7" lower_limit="239.0" upper_limit="291.0"/>
                    <measurement group_id="O3" value="122.5" lower_limit="110.7" upper_limit="135.5"/>
                    <measurement group_id="O4" value="230.7" lower_limit="207.8" upper_limit="256.0"/>
                    <measurement group_id="O5" value="115.5" lower_limit="104.9" upper_limit="127.2"/>
                    <measurement group_id="O6" value="254.2" lower_limit="230.5" upper_limit="280.3"/>
                    <measurement group_id="O7" value="128.5" lower_limit="116.5" upper_limit="141.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for safety for 42 days after each scheduled vaccination.</time_frame>
      <desc>Number of participants reported as &quot;At Risk&quot; is the number of participants with follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>ProQuad (Low Dose) After Injection 1</title>
          <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="E2">
          <title>ProQuad (Middle Dose) After Injection 1</title>
          <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="E3">
          <title>ProQuad (High Dose) After Injection 1</title>
          <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="E4">
          <title>M-M-R™ II + PUVV (Process Upgrade Varicella Vaccine)</title>
          <description>One M-M-R™ II (0.5-mL) SQ injection administered concomitantly with one PUVV (0.5-mL) SQ injection, at separate injection sites, on Day 0.</description>
        </group>
        <group group_id="E5">
          <title>ProQuad (Low Dose) After Injection 2</title>
          <description>One ProQuad™ (3.48 log10 plaque-forming units [PFU]/0.5-mL dose) subcutaneous (SQ) injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="E6">
          <title>ProQuad (Middle Dose) After Injection 2</title>
          <description>One ProQuad™ (3.97 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
        <group group_id="E7">
          <title>ProQuad (High Dose) After Injection 2</title>
          <description>One ProQuad™ (4.25 log10 PFU/0.5-mL dose) SQ injection administered on Day 0, followed by a second injection of the same material approximately 90 days later.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure, febrile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngotracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Respiratory distress, newborn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="286" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="286" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="289" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="297" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="253" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="258" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="254" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="59" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Otitis Media, Serous</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pain, Ear</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Candidiasis, Oral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, Infectious</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="136" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="98" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="99" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Viral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="110" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="93" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Viral Exanthema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Bite/Sting, Non-Venomous</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Congestion, Nasal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Congestion, Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Laryngotracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis, Contact</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Miliaria Rubra</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash, Diaper</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash, Measles/Rubella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash, Varicella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ecchymosis (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Erythema (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="52" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="51" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Swelling (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="387"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="377"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="353"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="361"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ecchymosis (M-M-R II Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ecchymosis (PUVV Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (PUVV Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (PUVV Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash (PUVV Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling (PUVV Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="381"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Seven (7) participants received unknown clinical material and 1 participant received diluent only; they were considered to be protocol violators and weren't included in the efficacy/safety analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

